Match!
Marco DiBonaventura
Pfizer
155Publications
21H-index
1,345Citations
Publications 157
Newest
Source
Source
Source
#1Millie D. Long (UNC: University of North Carolina at Chapel Hill)H-Index: 27
#2Timothy W. Smith (Pfizer)H-Index: 69
Last.D Quirk (Pfizer)H-Index: 3
view all 7 authors...
Source
#1Sandra MilevH-Index: 1
#2Marco DiBonaventura (Pfizer)H-Index: 21
Last.D Quirk (Pfizer)H-Index: 3
view all 9 authors...
AbstractAims: To evaluate the cost differences between a treatment strategy including tofacitinib (TOFA) vs treatment strategies including adalimumab (ADA), golimumab (GOL), infliximab (IFX), and v...
1 CitationsSource
Source
#1Fei Yang (Chinese PLA General Hospital)
#2Shengyuan Yu (Chinese PLA General Hospital)H-Index: 16
Last.Margarita Udall (Pfizer)H-Index: 7
view all 14 authors...
Introduction Few studies have examined the epidemiology of herpes zoster (HZ) and postherpetic neuralgia (PHN) in China. The aim of this study was to estimate the prevalence of HZ and PHN in China, and to examine the clinical characteristics of patients identified with PHN.
Source
Source
#1Marla DubinskyH-Index: 59
#2Andrew G. BushmakinH-Index: 24
Last.Alessandro ArmuzziH-Index: 41
view all 7 authors...
Source
#1Marla DubinskyH-Index: 59
#2Brian BresslerH-Index: 26
Last.Chinyu SuH-Index: 11
view all 9 authors...
Source
12345678910